Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

If Maggie O'Neil can't find a bone marrow match among family members, she'll have to turn to an anonymous donor through the ...

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

The analysis found that less than fifty percent of enrolled patients deceased after the median follow-up period of 13.5 months, indicating a median survival of over 13.5 Months in the trial vs.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

Ltd. have published findings from their work aiming to identify antigens that could represent novel targets for CAR T-cell therapies against acute myeloid leukemia (AML).